Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug Administration (FDA) approved the biotech's new non-opioid painkiller, Journavx. In a statement to the press, the company said it was the "first new class of pain treatment approved in more than 20 years." In response, Scotiabank raised its price target on VRTX by $3 to $433. Now recovered from its mid-December bear gap, VRTX is already up 15.7% since the start of 2025. Today's pop has the stock b ...

POLAND - 2024/11/21: In this photo illustration, the Vertex Pharmaceuticals company logo is seen ... [+] displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesVertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can potentially garner $4 billion in annual peak sales. For perspectiv ...

Stock Performance - Vertex Pharmaceuticals closed at $440 68, down 0 72% from the previous session, underperforming the S&P 500's gain of 0 92%, the Dow's gain of 0 31%, and the Nasdaq's gain of 2 03% [1] - Over the past month, the company's shares gained 11 15%, outperforming the Medical sector's gain of 3 83% and the S&P 500's gain of 0 81% [1] Earnings and Revenue - The company's upcoming earnings report is expected on February 10, 2025, with projected EPS of $4, reflecting a 4 76% decrease from the same quarter last year [2] - Revenue is expected to be $2 78 billion, up 10 29% from the prior-year quarter [2] Analyst Forecasts and Revisions - Recent revisions to analyst forecasts for Vertex Pharmaceuticals are important as they reflect changing near-term business trends [3] - Positive estimate revisions are generally a good sign for the company's business outlook [3] - The Zacks Consensus EPS estimate has shifted 0 34% downward over the past month [5] Valuation Metrics - Vertex Pharmaceuticals is trading at a Forward P/E ratio of 24 39, which is a premium compared to the industry average of 22 85 [6] - The company has a PEG ratio of 2, higher than the industry average of 1 39 for Medical - Biomedical and Genetics stocks [6] Industry Ranking - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 72, placing it in the top 29% of over 250 industries [7] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks within the groups [7] - Top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, t ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3%, and the Nasdaq, a tech-heavy index, added 1.28%.Shares of the drugmaker have appreciated by 4.83% over the course of the past month, outperforming the Medical sector's gain of 1.64% and the S&P 500's gain of 2.08%.Analysts and investors alike will be keeping a close eye on the performance of V ...

VRTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Vertex Pharmaceuticals Incorporated ...

Lost Money on Vertex Pharmaceuticals Incorporated(VRTX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky ...

Lost Money on Vertex Pharmaceuticals Incorporated(VRTX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation ...

Key Points Company and Industry Information 1. **Company Presentation**: Vertex Pharmaceuticals Incorporated (VRTX) is presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 [3]. 2. **Company Overview**: Vertex is a biotechnology company focused on the development and commercialization of innovative therapies for serious diseases [3]. 3. **Management Team**: The presentation includes key members of Vertex's senior management team, including Dr. Reshma Kewalramani (President and CEO), Charlie Wagner (Chief Financial Officer), Stuart Arbuckle (Chief Operating Officer), and David Altshuler (Chief Scientific Officer) [3]. Core Views and Arguments 1. **Unique Business Model**: Vertex has a unique business model, although the specific details of this model are not elaborated upon [4]. 2. **Focus on Innovation**: Vertex emphasizes its commitment to innovation and the development of new therapies for serious diseases [3]. Other Important Content 1. **Safe Harbor Statement**: The presentation includes a Safe Harbor Statement, reminding participants that forward-looking comments will be made and encouraging them to review the company's SEC disclosures for more detail [1]. 2. **Voice Apology**: The presenter, Dr. Reshma Kewalramani, apologizes for her voice quality due to a cold [1]. 3. **Conference Details**: The conference is the 43rd Annual J.P. Morgan Healthcare Conference, and the presentation takes place on January 13, 2025, at 10:30 AM ET [3].

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA approval for the first CRSPR-based gene therapy treatment for sickle cell anemia (SCA) called Casgevy, developed by Vertex Pharmaceuticals Inc. NASDAQ: VRTX. Sickle cell is a disease that causes red blood cells to form into a sickle-like shape, which can block blood flow, leading to more serious complications like pain and organ damage. It is caused by a mutation in the hemoglobin gene ...